Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing…

Posted: September 27, 2024 at 2:51 am

Company to host conference call today at 4:30 p.m. ET Company to host conference call today at 4:30 p.m. ET

See original here:
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing...

Related Posts